title: Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results.
abstract: In this study we assessed the prognostic significance of 90K/MAC-2BP serum levels in a group of 40 hepatocellular carcinoma patients. This glycoprotein is a new, interesting serum marker that reflects the immune reaction of the host against certain viral infections and tumors such as breast, ovarian and pancreatic cancer. Hepatocellular carcinoma (HCC) is one of the most widespread tumors in the world. AFP is currently the most useful marker for HCC, in spite of its poor diagnostic sensitivity. In this study 40 cirrhotic HCC patients were enrolled. The prevalence of viral hepatic infections in this group was 73% for HCV, 8% for HBV, and 8% for both viruses. Thirteen percent of the patients showed non-virus-related liver damage. 90K serum levels were assayed by an ELISA kit and AFP levels by a chemiluminescent enzyme immunometric system. The overall survival curves were estimated by the Kaplan-Meier method, taking into account age, sex, 90K and AFP serum levels. Statistical analysis showed a highly significant influence on overall survival of age below 70 years and 90K serum levels below the cutoff of 14 ng/mL. Serum AFP (< or = 20 ng/mL) had positive prognostic value only when it was associated with 90K levels (p < 0.02, log-rank).
authors.affiliation: Clinical Laboratory Unit, IRCCS "S. De Bellis", Castellana Grotte (Bari), Italy. minaiaco@tiscalinet.it
authors.forename: P A
authors.initials: PA
authors.lastname: Iacovazzi
authors.forename: V
authors.initials: V
authors.lastname: Guerra
authors.forename: S
authors.initials: S
authors.lastname: Elba
authors.forename: F
authors.initials: F
authors.lastname: Sportelli
authors.forename: O G
authors.initials: OG
authors.lastname: Manghisi
authors.forename: M
authors.initials: M
authors.lastname: Correale
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000473:pathology; D002352:Carrier Proteins; D002478:Cells, Cultured; D003933:Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008113:Liver Neoplasms / Q000097:blood* / Q000473:pathology; D008163:Luminescent Measurements; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism; D009363:Neoplasm Proteins / Q000097:blood*; D011379:Prognosis; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000378:metabolism; D016326:Extracellular Matrix Proteins
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D006023:Glycoproteins; D008074:Lipoproteins; D009363:Neoplasm Proteins; D000509:alpha-Fetoproteins; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins